BioStock Studio: Expres2ion’s CEO gives status update

Biotech ExpreS2ion Biotechnologies – that develops vaccines for covid-19, breast cancer, influenza and malaria – is currently conducting a rights issue of 73 million SEK. CEO Bent U. Frandsen visited BioStock’s studio to give a status update on the covid-19 project, which is being developed together with Bavarian Nordic, and to tell us more about the rights issue.

Watch the interview at biostock.se:

https://www.biostock.se/en/2022/04/biostock-studio-expres2ions-ceo-gives-status-update/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se